keyword
MENU ▼
Read by QxMD icon Read
search

Disease-modifying antirheumatic drugs

keyword
https://www.readbyqxmd.com/read/28740623/patient-access-to-reimbursed-biological-disease-modifying-antirheumatic-drugs-in-the-european-region
#1
Zoltán Kaló, Zoltán Vokó, Andrew Östör, Emma Clifton-Brown, Radu Vasilescu, Alysia Battersby, Edward Gibson
Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct costs against a background of restricted healthcare budgets. This study compares the size of RA patient populations with access to reimbursed bDMARDs across 37 European countries, Russia, and Turkey, according to their treatment eligibility defined by European League Against Rheumatism (EULAR) recommendations and national reimbursement criteria...
2017: Journal of Market Access & Health Policy
https://www.readbyqxmd.com/read/28737992/temporal-trends-in-use-of-biologic-dmards-for-rheumatoid-arthritis-in-the-united-states-a-cohort-study-of-publicly-and-privately-insured-patients
#2
Rishi J Desai, Daniel H Solomon, Yinzhu Jin, Jun Liu, Seoyoung C Kim
BACKGROUND: Ten biologic disease-modifying antirheumatic drugs (bDMARDs) are available as treatment for rheumatoid arthritis (RA), but relatively little is known about population-level time trends in the use of these agents. OBJECTIVE: To describe time trends in the use of bDMARDs in RA patients with private or public insurance in the United States. METHODS: Claims data from private (Optum Clinformatics, 2004-2015) and public (Medicaid Analytic eXtract [MAX], 2000-2010) insurance programs were used...
August 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28737988/patterns-of-care-for-biologic-dosing-outliers-and-nonoutliers-in-biologic-naive-patients-with-rheumatoid-arthritis
#3
Thomas Delate, Roxanne Meyer, Daniel Jenkins
BACKGROUND: Although most biologic medications for patients with rheumatoid arthritis (RA) have recommended fixed dosing, actual biologic dosing may vary among real-world patients, since some patients can receive higher (high-dose outliers) or lower (low-dose outliers) doses than what is recommended in medication package inserts. OBJECTIVE: To describe the patterns of care for biologic-dosing outliers and nonoutliers in biologic-naive patients with RA. METHODS: This was a retrospective, longitudinal cohort study of patients with RA who were not pregnant and were aged ≥ 18 and < 90 years from an integrated health care delivery system...
August 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28737837/drug-survival-and-reasons-for-discontinuation-of-the-first-biological-disease-modifying-antirheumatic-drugs-in-thai-patients-with-rheumatoid-arthritis-analysis-from-the-thai-rheumatic-disease-prior-authorization-registry
#4
Pongthorn Narongroeknawin, Parawee Chevaisrakul, Nuntana Kasitanon, Tasanee Kitumnuaypong, Ajanee Mahakkanukrauh, Boonjing Siripaitoon, Wanruchada Katchamart
AIM: To evaluate and compare the retention rate of biological disease-modifying antirheumatic drugs (bDMARDs) in real-life practice and identify risk factors related to remission and drug discontinuation in patients with rheumatoid arthritis (RA). METHOD: A total of 256 patients fulfilling criteria for RA and starting bDMARD between December 2009 and October 2014 were selected from the Rheumatic Disease Prior Authorization registry. Baseline demographic and clinical data were recorded...
November 5, 2016: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28737053/efficacy-of-baricitinib-in-the-treatment-of-rheumatoid-arthritis
#5
Christophe Richez, Marie-Elise Truchetet, Marie Kostine, Thierry Schaeverbeke, Bernard Bannwarth
Introduction Although the outcome for patients with rheumatoid arthritis (RA) has improved in the past decades, adequate disease control cannot be achieved in a substantial proportion of patients. New drugs with a novel mechanism of action, may represent a valuable addition to the current armamentarium. Areas covered This review focuses on the pharmacodynamics and pharmacokinetics of baricitinib. Furthermore, the article summarizes and comments the drug's efficacy and safety profile in RA patients. Expert opinion Baricitinib is an oral targeted synthetic (ts) disease-modifying antirheumatic drug (DMARD) that mainly inhibits JAK1 and JAK2...
July 24, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28730757/psoriatic-arthritis-treatment-regimens-therapy-duration-and-reasons-for-cessation-in-the-biologics-era-a-multi-centre-australian-study
#6
Kathleen Tymms, Ayano Kelly, Paul Bird, Hedley Griffiths, Julien de Jager, Geoff Littlejohn, Sandra Louw, Lynden Roberts, Peter Youssef, Jane Zochling, Dave Nichols
AIM: To describe the treatment regimens, duration of therapy and reasons for disease-modifying antirheumatic drug (DMARD) cessation in a large psoriatic arthritis (PsA) cohort. METHODS: A retrospective non-interventional multi-centre study using Audit4 electronic medical records, with de-identified, routinely collected clinical data from rheumatology practices in the OPAL consortium (Optimising Patient outcomes in Australian rheumatoLogy) during November 2015. Baseline characteristics, type and duration of conventional and biologic DMARDs (cDMARD and bDMARD, respectively), disease activity (Disease Activity Score of 28 joints C-reactive protein [DAS28-CRP]), and reasons for treatment cessation were recorded...
July 21, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28729087/real-world-effectiveness-of-biologic-disease-modifying-antirheumatic-drugs-for-the-treatment-of-rheumatoid-arthritis-after-etanercept-discontinuation-in-the-united-kingdom-france-and-germany
#7
Nanxin Li, Keith A Betts, Andrew J Messali, Martha Skup, Vishvas Garg
PURPOSE: The purpose of this study was to assess the real-world effectiveness of patients with rheumatoid arthritis (RA) who discontinued etanercept treatment and subsequently received another tumor necrosis factor α (TNF-α) inhibitor or a non-TNF-α biologic in the United Kingdom, France, and Germany. METHODS: Medical record data of patients with RA were collected from a panel of rheumatologists in the United Kingdom, France, and Germany. Patients were required to have a diagnosis of RA, be ≥18 years old, and have initiated use of another TNF-α inhibitor (adalimumab, certolizumab pegol, golimumab, or infliximab) or a non-TNF-α biologic (abatacept or tocilizumab) between January 2014 and May 2015 after discontinuing use of etanercept...
July 17, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28724442/impact-of-obesity-on-the-response-to-tumor-necrosis-factor-inhibitors-in-axial-spondyloarthritis
#8
Raphael Micheroli, Monika Hebeisen, Lukas M Wildi, Pascale Exer, Giorgio Tamborrini, Jürg Bernhard, Burkhard Möller, Pascal Zufferey, Michael J Nissen, Almut Scherer, Adrian Ciurea
BACKGROUND: Few studies have investigated the impact of obesity on the response to tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA). The aim of our study was to investigate the impact of different body mass index (BMI) categories on TNFi response in a large cohort of patients with axSpA. METHODS: Patients with axSpA within the Swiss Clinical Quality Management (SCQM) program were included in the current study if they fulfilled the Assessment in Spondyloarthritis International Society (ASAS) criteria for axSpA, started a first TNFi after recruitment, and had available BMI data as well as a baseline and follow-up visit at 1 year (±6 months)...
July 19, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28718769/pesticide-exposure-and-risk-of-rheumatoid-arthritis-among-licensed-male-pesticide-applicators-in-the-agricultural-health-study
#9
Armando Meyer, Dale P Sandler, Laura E Beane Freeman, Jonathan N Hofmann, Christine G Parks
BACKGROUND: The occupation of farming has been associated with rheumatoid arthritis (RA); pesticides may account for this association, but there are few studies. OBJECTIVES: We investigated associations between RA and use of pesticides in the Agricultural Health Study. METHODS: The study sample was drawn from male pesticide applicators enrolled in 1993-1997 who provided questionnaire data at baseline and at least once during follow-up (over a median 18 y; interquartile range 16-19)...
July 14, 2017: Environmental Health Perspectives
https://www.readbyqxmd.com/read/28700530/retrospective-study-of-patients-on-etanercept-therapy-for-rheumatic-diseases-in-patients-with-chronic-hepatitis-c-virus
#10
Nisarg P Gandhi, Augustine M Manadan, Joel A Block
OBJECTIVE: Treatment of rheumatic diseases with concurrent hepatitis C virus (HCV) infection is a therapeutic challenge. Etanercept has no known hepatotoxicity; however there is a concern for worsening of HCV infection-related liver disease due to immunosuppressive action of the drug. Here, we retrospectively assessed the safety of etanercept in rheumatologic disease in patients with chronic HCV. METHODS: A retrospective review was conducted in patients with chronic HCV infection who received etanercept for diagnosis of rheumatoid arthritis and psoriatic arthritis...
August 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28700520/current-practice-for-therapeutic-drug-monitoring-of-biopharmaceuticals-in-rheumatoid-arthritis
#11
Frédéric Medina, Chamaida Plasencia, Philippe Goupille, David Ternant, Alejandro Balsa, Denis Mulleman
The treatment of rheumatoid arthritis (RA) has largely improved in the biopharmaceutical era. These compounds, primarily tumor necrosis factor (TNF) inhibitors, are effective, but some patients may show poor response, sometimes because of the presence of antidrug antibodies (ADAs). In some instances, clinicians may increase or taper the dose depending on the clinical response. Besides the current clinical-based practice, a tailored strategy based on drug monitoring has emerged as a way to improve the use of these drugs...
August 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28688467/prediction-of-response-to-targeted-treatment-in-rheumatoid-arthritis
#12
REVIEW
C A Wijbrandts, P P Tak
Rheumatoid arthritis is an autoimmune syndrome presenting with chronic inflammation of the joints. Patients with the same diagnosis can present with different phenotypes. In some patients severe joint inflammation and early joint destruction are observed, whereas a milder phenotype can be seen in others. Conversely, patients with the same signs and symptoms may exhibit different immunological and molecular abnormalities. Since the introduction of early treatment in clinical practice, the treat to target principle, and new medicines such as biologic disease-modifying antirheumatic drugs, clinical remission can be achieved early in the disease course, albeit not in all patients...
July 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28679392/factors-associated-with-initial-or-subsequent-choice-of-biologic-disease-modifying-antirheumatic-drugs-for-treatment-of-rheumatoid-arthritis
#13
Yinzhu Jin, Rishi J Desai, Jun Liu, Nam-Kyong Choi, Seoyoung C Kim
BACKGROUND: Biologic disease-modifying antirheumatic drugs (DMARDs) are increasingly used for rheumatoid arthritis (RA) treatment. However, little is known based on contemporary data about the factors associated with DMARDs and patterns of use of biologic DMARDs for initial and subsequent RA treatment. METHODS: We conducted an observational cohort study using claims data from a commercial health plan (2004-2013) and Medicaid (2000-2010) in three study groups: patients with early untreated RA who were naïve to any type of DMARD and patients with prevalent RA with or without prior exposure to one biologic DMARD...
July 5, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28668812/cost-effectiveness-of-biological-disease-modifying-antirheumatic-drugs-for-the-treatment-of-rheumatoid-arthritis-implications-for-clinical-practice
#14
EDITORIAL
T Martijn Kuijper, Leander R Buisman, Johanna M Hazes, Angelique E Weel
No abstract text is available yet for this article.
July 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28665531/radial-extracorporeal-shock-wave-therapy-for-relief-of-arthralgia-in-rheumatoid-arthritis
#15
Yiming Liu, Tingjie Zhang, Yi Feng
More than one third of the population with rheumatoid arthritis require adjuvant analgesic treatment after antirheumatic therapy. In addition to analgesics, another option is radial extracorporeal shock wave therapy (rESWT), which is a novel physical therapy that has been successfully used in the treatment of many types of chronic soft tissue pain. We report a series of 15 patients who suffered from arthralgia after being on disease-modifying antirheumatic drugs for more than 3 months. Participants received rESWT for 3 months as an adjuvant therapy...
June 30, 2017: Pain Practice: the Official Journal of World Institute of Pain
https://www.readbyqxmd.com/read/28660550/clinical-and-economic-evaluation-of-repository-corticotropin-injection-a-narrative-literature-review-of-treatment-efficacy-and-healthcare-resource-utilization-for-seven-key-indications
#16
REVIEW
Michael Philbin, John Niewoehner, George J Wan
INTRODUCTION: Repository corticotropin injection (RCI; H.P. Acthar(®) Gel; Mallinckrodt Pharmaceuticals Inc., Hampton, NJ) is a highly purified, prolonged-release porcine preparation of adrenocorticotropic hormone (ACTH) analogue that is FDA-approved for treatment of 19 autoimmune and inflammatory disorders. The diverse physiological actions of RCI at the melanocortin receptors (MCRs) affect processes involved in inflammation, pigmentation, steroidogenesis, and immunomodulation. Although RCI has been approved to treat inflammatory and autoimmune diseases for more than 60 years, recent progress in understanding both MCRs and the effects of RCI in modulating immune responses has led to increased interest in RCI as a therapeutic choice...
June 28, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28644744/add-on-iguratimod-as-a-therapeutic-strategy-to-achieve-remission-in-patients-with-rheumatoid-arthritis-inadequately-responding-to-biological-dmards-a-retrospective-study
#17
Ayaka Yoshikawa, Shuzo Yoshida, Yuko Kimura, Nao Tokai, Yohei Fujiki, Takuya Kotani, Yoko Matsumura, Tohru Takeuchi, Shigeki Makino
OBJECTIVES: In this study, iguratimod (IGU) was added to rheumatoid arthritis (RA) patients inadequately responding to 24-week or longer treatment with biological disease-modifying antirheumatic drug (bDMARDs), its effectiveness was assessed, and factors contributing to remission were evaluated. METHODS: RA patients who fulfilled the following criteria were included: (i) ≥ 24-week of bDMARDs; (ii) 2.6 < disease activity score (DAS) 28-erythrocyte sedimentation rate (ESR) < 5...
June 23, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28638693/management-of-the-temporomandibular-joint-in-inflammatory-arthritis-involvement-of-surgical-procedures
#18
REVIEW
Rory C O'Connor, Fiona Fawthrop, Rami Salha, Andrew J Sidebottom
Many conditions may affect the temporomandibular joint (TMJ), but its incidence in individual joint diseases is low. However, inflammatory arthropathies, particularly rheumatoid and psoriatic arthritis and ankylosing spondylitis, appear to have a propensity for affecting the joint. Symptoms include pain, restriction in mouth opening, locking, and noises, which together can lead to significant impairment. Jaw rest, a soft diet, a bite splint, and medical therapy, including disease-modifying antirheumatic drugs (DMARDs) and simple analgesia, are the bedrock of initial treatment and will improve most symptoms in most patients...
June 2017: European Journal of Rheumatology
https://www.readbyqxmd.com/read/28634103/undetectable-mannose-binding-lectin-and-corticosteroids-increase-serious-infection-risk-in-rheumatoid-arthritis
#19
Graeme J Carroll, Krista Makin, Maxine Garnsey, Max Bulsara, Bronwyn V Carroll, Shona M Curtin, Erin M Allan, Andrew McLean-Tooke, Christine Bundell, Monica L Kemp, Pooja Deshpande, Dana Ihdayhid, Sophie Coleman, Tracie Easter, James Triplett, Timothy Disteldorf, C Helen Marsden, Michaela Lucas
BACKGROUND: Infection is the leading cause of death in rheumatoid arthritis (RA). Corticosteroid (CS) use is a known and important risk factor for serious infections (SIs). Mannose binding lectin (MBL) is a genetically determined component of the innate immune system implicated in neonatal infections. OBJECTIVE: Our aim was to determine whether MBL deficiency is a risk factor for SIs in RA and to compare it with CS use and also synthetic and biologic disease-modifying antirheumatic drug (DMARD) therapy...
June 17, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28631046/adherence-of-rheumatoid-arthritis-patients-to-biologic-disease-modifying-antirheumatic-drugs-a-cross-sectional-study
#20
Natalia Mena-Vazquez, Sara Manrique-Arija, Lucía Yunquera-Romero, Inmaculada Ureña-Garnica, Marta Rojas-Gimenez, Carla Domic, Francisco Gabriel Jimenez-Nuñez, Antonio Fernandez-Nebro
The aims of this study were to evaluate adherence of rheumatoid arthritis (RA) patients to biological disease-modifying antirheumatic drugs (bDMARDs), identify potential risk factors, and analyze the discriminative ability of the Morisky-Green test (MGT) to detect bDMARD nonadherence. One hundred and seventy-eight adult RA patients treated with bDMARDs were included. Adherence was measured using the medication possession ratio (MPR) of the previous 6 months. An MPR >80% was considered good adherence. Patient demographics, clinical characteristics, and MGT scores were assessed through a standardized clinical interview at the cross-sectional date...
June 19, 2017: Rheumatology International
keyword
keyword
116670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"